StockData

Atara Biotherapeutics vs Dyadic International

ATRA and DYAI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ATRA and DYAI compare

Atara Biotherapeutics is the larger company, worth 5.5 times as much as Dyadic International ($64.2M against $11.7M).

Dyadic International grew revenue faster over the last twelve months (−7.6% versus −96.7% for Atara Biotherapeutics).

Dyadic International keeps more of each dollar of sales as profit, with a net margin of −227% compared with −269% at Atara Biotherapeutics.

Dyadic International scores higher on the StockData Score (7 against 3 for Atara Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricATRADYAI
Size and price
Market cap$64.2M$11.7M
Share price$6.40$0.320
Change, 1 year−52.2%−64.6%
Change, 5 years−98.5%−91.4%
Beta (5Y)2.011.44
Employees145
StockData Score
Total score37 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S10.4×3.8× (better)
Growth
Revenue growth (TTM)−96.7%−7.6% (better)
Revenue growth, 5Y average–14.0%
Net income growth (TTM)−388%–
Profitability
Gross margin–17.9%
Operating margin−230% (better)−237%
Net margin−269%−227% (better)
Return on equity–−47256%
Financial health
Interest coverage−5.0×–
Current ratio1.98 (better)1.69
Altman Z-score−136.13−18.95 (better)
Piotroski F-score5 (better)2
Dividends and buybacks
Buyback yield−14.4%–
Shareholder yield−14.4%0.00% (better)
Ownership
Held by institutions44.5%12.7%
Held by insiders55.5%28.0%
Insider net buying, 12 months$2.0M (better)−$125K
Short interest, % of float6.6%0.32%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.